{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:30:33Z","timestamp":1781566233826,"version":"3.54.5"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We present a case of severe juvenile dermatomyositis with limited response to steroids in an adolescent who developed symptoms within hours after receiving Pfizer BNT162b2 coronavirus disease 2019 vaccine. The patient presented with severe weakness of proximal muscles, dyspnoea, and tachycardia. His muscle enzymes were raised, and he was diagnosed with severe juvenile dermatomyositis following magnetic resonance imaging and muscle biopsy. His management was challenging, requiring multidisciplinary input, and difficult decisions with regard to the appropriate immunomodulatory treatments. The patient had to undergo escalating immunosuppressive treatments before he began to recover clinically and biochemically. To our knowledge, this is the first case in an adolescent although a few cases of similar presentations following coronavirus disease 2019 vaccination have been reported in adults. Elucidating the potential relationship of the vaccine with this severe myopathy in an adolescent is important for global vaccination policies, but avoiding the conflation of association with causation is also crucial in the context of the pandemic.<\/jats:p>","DOI":"10.1093\/mrcr\/rxac097","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T07:36:57Z","timestamp":1671781017000},"page":"410-415","source":"Crossref","is-referenced-by-count":3,"title":["A rare presentation of rapidly progressing myopathy in an adolescent"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1441-0145","authenticated-orcid":false,"given":"Jack","family":"Pepys","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J","family":"Borchert","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narmathy","family":"Thambirajah","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Daruwalla","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Apostolopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic G","family":"O\u2019Donovan","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Ham","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Brierley","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"2023061920013031300_R1","article-title":"Coronavirus Pandemic (COVID-19)","volume-title":"Our World Data","author":"Ritchie","year":"2020"},{"key":"2023061920013031300_R2","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10030439","article-title":"Short-term adverse events and antibody response to the BNT162b2 SARS-CoV-2 vaccine in 4156 health care professionals","volume":"10","author":"Azzolini","year":"2022","journal-title":"Vaccines"},{"key":"2023061920013031300_R3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2021","journal-title":"Immunology"},{"key":"2023061920013031300_R4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"2023061920013031300_R5","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"2023061920013031300_R6","doi-asserted-by":"crossref","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2023061920013031300_R7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-021-08920-y","article-title":"An Italian multicenter study on anti-NXP2 antibodies: clinical and serological associations","volume":"63","author":"Fredi","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023061920013031300_R8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023061920013031300_R9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023061920013031300_R10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023061920013031300_R11","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2016.00064","article-title":"Idiopathic inflammatory myopathies: clinical approach and management","volume":"7","author":"Malik","year":"2016","journal-title":"Front Neurol"},{"key":"2023061920013031300_R12","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2023061920013031300_R13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaneurol.2020.0673","article-title":"Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies","volume":"77","author":"Inoue","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023061920013031300_R14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/BOR.0000000000000844","article-title":"Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies","volume":"33","author":"De Santis","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2023061920013031300_R15","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s00296-022-05176-3","article-title":"New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review","volume":"42","author":"Holzer","year":"2022","journal-title":"Rheumatol Int"},{"key":"2023061920013031300_R16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.autrev.2014.01.054","article-title":"On the relationship between human papilloma virus vaccine and autoimmune diseases","volume":"13","author":"Pellegrino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2023061920013031300_R17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2023061920013031300_R18","doi-asserted-by":"crossref","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2023061920013031300_R19","doi-asserted-by":"crossref","first-page":"20611","DOI":"10.1074\/jbc.M201440200","article-title":"The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains*","volume":"277","author":"Kimura","year":"2002","journal-title":"J Biol Chem"},{"key":"2023061920013031300_R20","article-title":"Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination","author":"Lee","year":"2022","journal-title":"Postgrad Med J"},{"key":"2023061920013031300_R21","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2022.37.e32","article-title":"Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination","volume":"37","author":"Gouda","year":"2022","journal-title":"J Korean Med Sci"},{"key":"2023061920013031300_R22","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-022-00250-6","article-title":"Dermatomyositis post vaccine against SARS-COV2","volume":"6","author":"Camargo Coronel","year":"2022","journal-title":"BMC Rheumatol"},{"key":"2023061920013031300_R23","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"2023061920013031300_R24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.transci.2015.07.005","article-title":"Plasma-exchange as a \u201crescue therapy\u201d for dermato\/polymyositis in acute phase. Experience in three young patients","volume":"53","author":"Cozzi","year":"2015","journal-title":"Transfus Apher Sci"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxac097\/48504490\/rxac097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/410\/50646425\/rxac097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/410\/50646425\/rxac097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T20:06:14Z","timestamp":1687205174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/7\/2\/410\/6958250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,23]]},"published-print":{"date-parts":[[2023,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxac097","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,12,23]]}}}